Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.31 USD
+0.02 (5.03%)
Updated Jul 3, 2024 12:58 PM ET
After-Market: $0.31 0.00 (-0.96%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
Brokerage Reports
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 1 - 20 ( 96 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q24: More ALG.APV-527 Data, APVO436/Ven/Aza 1st-Line AML Trial Starts Soon
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q23: New ALG.APV-527 Data APVO436/Ven/Aza 1st-Line AML Trial Starts Soon
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23: APVO436 Phase 2 On Deck, ALG.APV527 In Phase 1, Funded Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q23: APVO436 Phase 2 To Start, ALG.APV527 Data by YE23, Funded Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New Positive Phase 1b APVO436 Data - DoR, Response Rate, Transplant Rate
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Clinical Pipeline Progressing, Funded Into Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Clinical Pipeline Progressing, Funded Into Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in ALG.APV-527 Phase 1 Trial in 5T4+ Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J